TLK286

Phase 3Small molecule

TTelik

TLK286 is one of 82 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

TLK286

TTelik

Phase 3

1 3

Zolymbus

AbbVie

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Avastin

Roche

Preclinical

4 9

Paracetamol

GSK

Preclinical

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer5 trials

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Completed·TTelik·Phase 3·NCT00057720·440 enrolled

TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Completed·TTelik·Phase 3·NCT00102973·244 enrolled

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Completed·TTelik·Phase 1/2·NCT00052065·28 enrolled

Show 2 more trials

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Completed·TTelik·Phase 2·NCT00038428·40 enrolled

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Completed·TTelik·Phase 1/2·NCT00051948·28 enrolled

Non-Small Cell Lung Cancer4 trials

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·TTelik·Phase 3·NCT00080340·520 enrolled

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer

Completed·TTelik·Phase 1/2·NCT00047801·28 enrolled

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Completed·TTelik·Phase 2·NCT00040638·40 enrolled

Show 1 more trial

Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Completed·TTelik·Phase 1/2·NCT00088556·100 enrolled

Breast Cancer1 trial

Phase 2 Study of TLK286 in Metastatic Breast Cancer

Completed·TTelik·Phase 2·NCT00035841·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for TLK286. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TLK286 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TLK286. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Telik company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTelik

TLK286

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer5 trials

Non-Small Cell Lung Cancer4 trials

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News